Neuroprotective effect of Da Chuanxiong Formula against cognitive and motor deficits in a rat controlled cortical impact model of traumatic brain injury
Graphical abstract
Introduction
Traumatic brain injury (TBI) is an injury caused by a bump, blow, jolt or penetrating wound to the head, which disrupts the normal function of the brain included cognitive, behavioral and psychosocial deficits. Road traffic accidents, falls, violence, work and sports related injuries are the major etiologies of traumatic brain injury. According to the World Health Organization, the global incidence rate of TBI is likely 600 per 100,000 annually. TBI is predicted to become one of the major causes of death and disability by the year 2020 (Hyder et al., 2007). In China, the average annual number of TBI cases is 3–4 million (Liu, 2015). The highest incidence of TBI are found in young people at age 19 or younger and older adults over 75 years, predominantly males (Leo and McCrea, 2016). The annual economic cost included lifetime medical costs and productivity losses of TBI in the United States is estimated to be more than $60 billion (Brown et al., 2008). In addition, patients with TBI increased the risk to develop neurodegenerative disorders such as Alzheimer disease, chronic traumatic encephalopathy, amyotrophic lateral sclerosis and Parkinson disease due to its multiple and multidirectional biochemical events (Gardner et al., 2015, Gupta and Sen, 2016). Overall, TBI is a critical public health problem worldwide, which severely affects the quality of the affected person's daily life and creates a financial burden for families and societies (Faul and Coronado, 2015).
TBI is a highly complex process and manifested in functional deficits due to both primary and secondary mechanisms. Primary injury refers to the immediate mechanical damage at the time of injury, resulting in necrotic cell death, shearing and tearing of blood vessels, neurons, glia and axons, and initiation of secondary injury. Secondary injury evolves over hours to days, even months, following the primary injury. It is the consequence of ongoing metabolic, cellular and molecular changes which cause further damage. Both primary craniocerebral injury and secondary lesions can induce oxidative stress, inflammation, brain edema, blood-brain barrier (BBB) damage and eventually result in neuronal cell death and functional deficits (Xiong et al., 2013). Among of these mechanisms, neuroinflammation is widely consider as a vital factor which contributes to the initiation and progression of the secondary phase of TBI, leading to the widespread cell death, suppression of NSCs proliferation and neurogenesis, and cortical as well as hippocampal neurodegeneration. The inflammatory responses are regulated by activated astrocyte and microglia, along with infiltrating macrophage, which are able to upregulate and secrete many inflammatory mediators such as cytokines, nitric oxide (NO) and chemotactic factors following TBI (Karve et al., 2016, Mishra et al., 2016). These inflammation mediators participate in multiple pathways, which lead to energy depletion, protein aggregation and excitotoxicity. Eventually, TBI causes structural damage and neurological deficits, for instance, cognitive impairments and motor dysfunctions, directly related to cortical and hippocampal disruption with neuronal loss (Finnie, 2013, Xiong et al., 2009). Given the irreversibility of the primary injury, therapeutic targets for TBI focus on the secondary damages. Over the last three decades, more than 40 phase II and phase III clinical trials testing neuroprotective agents designed to enhance morphologic and functional recovery following TBI. However, the reported efficacy of numerous preclinical experimental therapies has not been translated into successful clinical trials. One possible reason is most of the researches focused exclusively on single therapy (Stein et al., 2015). The multifaceted and overlapping pathophysiological processes of TBI justifies the combination use of drugs for multiple molecular targets. In this regard, Chinese herbal medicine could be a new therapeutic strategy for TBI because it is usually a mixture of several constituents with diverse pharmacological functions which can simultaneously act at multiple sites (Yang et al., 2016).
Da Chuanxiong Formula (DCXF) is one of the most representative herbal formulas in traditional Chinese medicine (TCM). It was first recorded in “Xuan Ming Lun Fang” by Wan-Su Liu in Jin Dynasty. It contains dried rhizomes of Ligusticum chuanxiong Hort., umbelliferae (Chuanxiong Rhizoma, called as Chuanxiong in China, CR) and Gastrodia elata Bl., Orchidaceae (Gastrodiae Rhizoma, called as Tianma in China, GR) in the mass ratio of 4:1. This formula has been widely used to treat brain diseases like headache and migraine caused by blood stasis and wind pathogen. In DCXF, CR is employed as the monarch drug to promote “Qi” circulation in blood, expel wind and alleviate pain. The other herb, GR is used as the auxiliary drug to tranquilize the wind, terminate convulsion, calm the liver and suppress excessive “Yang”. Modern pharmacological investigations have shown that DCXF possesses therapeutic efficacies on various brain problems, including headache, migraine, vertigo, dementia, stroke and cerebral arteriosclerosis, due to its abilities to improve cerebral blood supply and blood vessel elasticity, decrease BBB disruption and edema formation, inhibit inflammation and nerve cell apoptosis, and reduce intracellular free calcium concentration (Wang et al., 2013). However, the therapeutic effect of DCXF on TBI has not been reported yet. Additionally, the guidelines of pharmacologic intervention for TBI is to developed pharmacologic solutions that can maximize efficacy and directly reduce cognitive and motor deficits after TBI (Elovic et al., 2008). According to the guidelines, the ultimate goal of any clinical study on TBI treatment is to address neurologic motor and cognitive problems and the experimental TBI researches also need to focus on the motor and cognitive function recovery following brain injury (Fujimoto et al., 2004). Thus, we investigated the neuroprotective efficacy of DCXF on cognitive and motor deficits using a well-established controlled cortical impact (CCI) model of TBI (Brody et al., 2007, Lam et al., 2016). In the present study, we demonstrate for the first time that DCXF attenuates both cognitive and motor impairments in the CCI-induced TBI rat model by Morris water maze test, acceleration rotarod motor test and catwalk quantitative gait analysis test, respectively, and its possible mechanisms that occur in the brain.
Section snippets
Chemicals and reagents
All chemicals were purchased from Sigma Aldrich (MO, USA) unless otherwise specified. Mouse anti-GFAP antibody was obtained from Abcam (MA, USA), rabbit anti-Iba-1 antibody was purchased from Wako (Osaka, Japan) and mouse anti-nestin antibody was obtained from Santa Cruz (CA, USA). Relative secondary antibodies EnVision™ HRP-conjugated goat anti-mouse immunoglobulins were purchased from Dako (Cytomation, Denmark), biotinylated goat anti-rabbit and peroxidase-labeled streptavidin were obtained
Effect of DCXF on the body weight of the rats
From the results, the body weight of the rats was not affected by the TBI surgical procedures or DCXF treatment (Fig. 1A), which showed a progressive and similar weight gain during the experimental period. The results indicated that the different changes of subsequent experiments were not due to body weight alterations.
DCXF decreased brain edema and attenuated BBB disruption after TBI
The brain water content was dramatically increased in the TBI group compared to the sham group (p < 0.0001) on day 3 after TBI (Fig. 1B). DCXF treatment significantly decreased
Discussion
The CCI-induced TBI model is a highly reliable and convenient model for preclinical TBI research in terms of controlled impact and quantifiable biomechanical parameters. This model can produce consistent histological damage and behavioral deficits similar to those observed in human patients (Osier and Dixon, 2016). It has been shown to be an important model for studying the pathophysiology of the secondary processes of TBI. Neuronal cell death and degeneration, astrocyte and microglia
Acknowledgments
This study was financially supported by the Food and Health Bureau, Hong Kong, Special Administration Region, Health and Medical Research Fund (no. 12134111).
Contribution of authors
Zhi-Ke Liu: perform the animal experiments, manuscript writing.
Chun-Fai Ng: analyze the data.
Hoi-Ting Shiu: analyze the data.
Hing-Lok Wong: analyze the data.
Wai-Ching Chin: analyze the data.
Jin-Fang Zhang: prepare for herbal extracts.
Ping-Kuen Lam: study design and manuscript review.
Wai-Sang Poon: study design and manuscript review.
Clara Bik-San Lau: study design and manuscript review.
Ping-Chung Leung: study concept, design and manuscript review.
Chun-Hay Ko: study concept, design and manuscript
References (51)
- et al.
Congenital and acquired brain injury. 1. Epidemiology, pathophysiology, prognostication, innovative treatments, and prevention
Arch. Phys. Med. Rehabil.
(2008) - et al.
Congenital and acquired brain injury. 4. Outpatient and community reintegration
Arch. Phys. Med. Rehabil.
(2008) - et al.
Epidemiology of traumatic brain injury
Handb. Clin. Neurol.
(2015) - et al.
Ligustilide alleviates brain damage and improves cognitive function in rats of chronic cerebral hypoperfusion
J. Ethnopharmacol.
(2012) - et al.
Motor and cognitive function evaluation following experimental traumatic brain injury
Neurosci. Biobehav. Rev.
(2004) - et al.
New insights into the ameliorative effects of ferulic acid in pathophysiological conditions
Food Chem. Toxicol.
(2017) - et al.
Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats
Exp. Neurol.
(2013) - et al.
Ligustilide prevents cognitive impairment and attenuates neurotoxicity in D-galactose induced aging mice brain
Brain Res.
(2015) Current status and development of traumatic brain injury treatments in China
Chin. J. Traumatol. = Zhonghua chuang shang za zhi
(2015)- et al.
A traditional Chinese formula composed of Chuanxiong Rhizoma and Gastrodiae Rhizoma (Da Chuanxiong Formula) suppresses inflammatory response in LPS -induced RAW 264.7 cells through inhibition of NF-kappaB pathway
J. Ethnopharmacol.
(2017)
Assessing gait impairment following experimental traumatic brain injury in mice
J. Neurosci. Methods
The aqueous extract of rhizome of Gastrodia elata Blume attenuates locomotor defect and inflammation after traumatic brain injury in rats
J. Ethnopharmacol.
iTRAQ-based proteomic analysis of tetramethylpyrazine inhibition on lipopolysaccharide-induced microglial activation
Life Sci.
Neurogenesis after traumatic brain injury
Neurosurg. Clin. N. Am.
Recent developments in clinical trials for the treatment of traumatic brain injury
Handb. Clin. Neurol.
Tetramethylpyrazine promotes proliferation and differentiation of neural stem cells from rat brain in hypoxic condition via mitogen-activated protein kinases pathway in vitro
Neurosci. Lett.
Gastrodin ameliorates depression-like behaviors and up-regulates proliferation of hippocampal-derived neural stem cells in rats: involvement of its anti-inflammatory action
Behav. Brain Res.
Gastrodin prevents motor deficits and oxidative stress in the MPTP mouse model of Parkinson's disease: involvement of ERK1/2-Nrf2 signaling pathway
Life Sci.
Protection against beta-amyloid-induced neurotoxicity by naturally occurring Z-ligustilide through the concurrent regulation of p38 and PI3-K/Akt pathways
Neurochem. Int.
TIMP-1/MMP-9 imbalance in brain edema in rats with fulminant hepatic failure
J. Surg. Res.
Evidence-based review of oral traditional Chinese medicine compound recipe administration for treating weight drop-induced experimental traumatic brain injury
BMC Complement. Altern. Med.
The rhizome of Gastrodia elata Blume - an ethnopharmacological review
J. Ethnopharmacol.
Ligustilide inhibits microglia-mediated proinflammatory cytokines production and inflammatory pain
Brain Res. Bull.
Experimental traumatic brain injury
Exp. Transl. Stroke Med.
Blood-brain barrier dysfunction following traumatic brain injury
Metab. Brain Dis.
Cited by (26)
Chinese herbal medicine in brain injury and other neurological disorders
2023, Treatments, Nutraceuticals, Supplements, and Herbal Medicine in Neurological DisordersClassical prescription Dachuanxiong Formula delays nitroglycerin-induced pain response in migraine mice through reducing endothelin-1 level and regulating fatty acid biosynthesis
2022, Journal of EthnopharmacologyCitation Excerpt :The coefficients of determination (R2) were all >0.99 (Table 2), which indicated that the method used displayed good linearity for the analytes within the tested range. A low dose (1 × human equivalent) and a high dose (5 × human equivalent) of DCXF were used to study the effects of DCXF in NTG-induced migraine mice, these doses were chosen according to a previous study (Liu et al., 2018). The body weights of the experimental mice were measured before, during and after DCXF treatment, and they remained unchanged throughout the whole experiment in all groups (Fig. 2A).
Structural characterization of two novel polysaccharides from Gastrodia elata and their effects on Akkermansia muciniphila
2021, International Journal of Biological MacromoleculesCitation Excerpt :It is a precious traditional Chinese medicine (TCM) with thousands of years of clinical application. It is reported that G. elata has therapeutic neuroactive effects, such as anti-convulsion [1,2], improving memory [3], preventing senescence [4], neuroprotection [5], etc. [6–9]. In recent years, studies have shown that intestinal flora abnormalities are associated with a variety of diseases, including amyotrophic lateral sclerosis [10], diabetes [11,12], Alzheimer's disease [13], etc. [14–16].
TMT-based proteomics analysis reveals the protective effects of Xuefu Zhuyu decoction in a rat model of traumatic brain injury
2020, Journal of EthnopharmacologyCitation Excerpt :Fortunately, traditional Chinese medicine (TCM) is famous for their multi-target effects and network regulations (Sucher, 2013). TCM achieves satisfied curative effects to treat TBI (Liu et al., 2018; Wang et al., 2016a; Wang et al., 2016b). As one of classic TCM prescriptions, Xuefu Zhuyu decoction (XFZYD) was first mentioned in the late Qing Dynastyin by Qingren Wang in the book “Yilin Gaicuo”.